How MOCART scoring reads a cartilage repair

When a 12-month MRI is arranged after ChondroFiller treatment, the radiologist is not simply looking for whether something has 'filled in'. They apply a structured scoring framework called MOCART 2.0 — a validated tool that converts what is visible on the scan into a number between 0 and 100.

Think of it as a checklist of how well the repair tissue blends with everything around it. The score weighs up how much of the original defect has been filled, how cleanly the repair tissue meets the edge of the surrounding native cartilage, how smooth the surface looks, and whether the signal characteristics of the new tissue resemble healthy cartilage. Bony changes beneath the repair — such as transient fluid signal in the subchondral layer — are factored in too.

A score of 100 would represent a scan effectively indistinguishable from the surrounding joint surface; a higher score consistently indicates more complete structural repair. MOCART 2.0 was developed specifically to improve consistency between readers, achieving an inter-rater reliability of approximately 0.875 compared with 0.759 for the original version — which matters when comparing results across clinics and studies.

Crucially, the score is not a single pass-or-fail gate. It is recorded at set points — typically four weeks, six months, and twelve months — precisely because scaffold-based repair matures gradually, and a single snapshot rarely tells the whole story.

The 12-month trajectory: how scores change from injection to one year

Receiving a 12-month MOCART result in the low-to-mid 80s is, for most patients, exactly the expected destination — and understanding the journey that produced it matters as much as the number itself.

European multi-site post-market follow-up data compiled by Jerosch and colleagues trace the trajectory clearly: a mean MOCART of 65.3 at four weeks, rising to 81.6 at twelve months, then consolidating to between 81.6 and 84.3 at three years. Two independent cohorts confirm the same arc. The 2016 prospective randomised multicentre trial (n=13 ChondroFiller patients) and a 2024 knee series by Simeonov (n=17, mean age 31) both recorded statistically significant structural improvement at every measured interval through to one year (p<0.05). Across all published one-year results, values cluster in the 70–87 range, with the 81–84 band the figure most consistently cited as the twelve-month headline.

The four-week scan — sometimes arranged to confirm initial scaffold positioning — should not be read as a maturity indicator. A reading in the mid-60s at that stage sits precisely where the data predict it should. Equally, the 81–84 figure at twelve months is not a ceiling: the further consolidation seen between one and three years in the Jerosch PMCF data suggests the repair tissue continues refining well beyond the one-year appointment.

It is worth noting plainly that the key knee cohorts remain small — fewer than 20 patients in each series — so published values represent directional evidence rather than population-wide guarantees.

What a score above 80 looks like on the scan

Of these structural qualities, volumetric fill is the most intuitive: a score above 80 corresponds directly to more than 80% of the original defect volume occupied by repair tissue. In practical terms, the lesion that once appeared as a bare patch on the articular surface is now largely reconstituted — not by injected material alone, but by the patient's own progenitor cells drawn into the scaffold through acellular matrix-induced chondrogenesis.

That cell-recruitment process is measurable. A 2025 ex vivo osteochondral study found a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14 — confirming the scaffold actively populates rather than passively occupying space, and explaining why MOCART values continue rising for months after treatment.

The peripheral integration finding is equally significant. Rather than a plug of repair tissue sitting in isolation, a score in the 81–84 range reflects good-to-complete merging at the defect margins — the repair zone connects to the surrounding native cartilage rather than leaving a visible boundary or gap.

On surface congruence, the scan reads as acceptably smooth: not the fibrillated or fissured contour of a deteriorating lesion, and not the uneven texture that often accompanies scar-like fibrocartilage. The signal intensity of the repair tissue similarly trends towards the appearance of normal hyaline cartilage rather than the low-signal appearance associated with microfracture repair alone — an important distinction when considering likely tissue quality.

Bone marrow oedema at 12 months: what transient changes mean

A 12-month scan report that mentions 'bone marrow oedema' in the subchondral region can understandably give patients pause — but this finding calls for context rather than alarm.

Subchondral BME arises when the repair tissue is still actively maturing and the underlying bone is responding to mechanical load. At twelve months, the scaffold has recruited the patient's own cells and the defect is largely filled, yet remodelling is not yet complete. BME appearing as a minor MOCART subchondral abnormality at this stage is a recognised feature of the active repair phase, not evidence that the scaffold has failed. It typically normalises on scans arranged at the two- or three-year interval, consistent with the broader maturation the Jerosch PMCF data document between one and three years.

This dynamic also clarifies why post-procedure weight-bearing restrictions are protective in a specific mechanical sense. In-vitro biomechanical testing confirms that ChondroFiller shows initial instability under cyclic loading; delaying full joint load until stable defect filling is achieved is the measure that allows the scaffold to mature without disruption.

Clinicians reviewing a twelve-month report should weigh any subchondral signal change against the overall picture — a rising MOCART trajectory, sound peripheral integration, and a patient who is functionally improving — rather than reading an isolated BME finding as a stand-alone verdict on the repair.

When the scan looks good but symptoms lag — and vice versa

Structural maturation and symptom recovery do not run on the same clock — and understanding this matters as much as knowing the MOCART number itself.

Functional scores, measured by IKDC, rise sharply after ChondroFiller treatment: from a pre-treatment average of approximately 48 to around 80 by twelve months, a gain of roughly 30 points that is close to double the 16.7-point minimally clinically important difference. That is a meaningful recovery by any clinical benchmark. Yet the 2024 Simeonov cohort (n=17) found no statistically significant difference between six- and twelve-month IKDC values — functional improvement appears to plateau around mid-year while MOCART scores continue to mature past the one-year mark.

Neither observation undermines the other. A strong scan result at twelve months does not guarantee the patient will feel equivalently well by that point; equally, a patient reporting good function may still have measurable structural maturation under way that will only be apparent on a later scan. The two trajectories are running in parallel rather than in step.

This is why rehabilitation milestones should draw on both sources of evidence. A treating clinician using scan findings and patient-reported outcomes together is better placed to calibrate loading progression than one relying on either measure alone.

Who gets the best 12-month MRI results

Patient selection is ultimately what separates the patients who reach the mid-80s MOCART range from those who do not — more so than any other variable in the published data.

The evidence is clearest in the hip series. Mazek's 2021 prospective cohort (n=26) found that patients with Tönnis grade 2–3 osteoarthritis achieved substantially worse outcomes than those treated for isolated focal defects in a well-preserved joint. Among the 21 evaluable patients without advanced OA, 17 (81%) reported good or excellent results at three to five years — consistent with the 70–85% success rate cited across the broader literature. Those strong structural scores at twelve months reflect, in part, a well-matched indication from the outset, not simply what the scaffold does in isolation.

Some limitations in the current evidence base are worth framing clearly. Most published knee cohorts remain small (n<20), no randomised head-to-head MOCART comparison against autologous chondrocyte implantation or matrix-induced techniques exists for ChondroFiller at twelve months specifically, and compositional MRI tools such as T2 mapping — which would characterise biochemical tissue quality beyond morphological appearance — have not yet been applied to ChondroFiller cohorts. As larger comparative trials accumulate, confidence in the trajectory already documented by smaller prospective series should increase rather than diminish.

Establishing suitability before treatment is therefore the practical priority. At London Cartilage Clinic, pre-treatment assessment combines imaging review with clinical findings to determine whether an acellular scaffold pathway is appropriate for the specific defect and joint in question; appointments can be arranged via londoncartilage.com. The twelve-month scan, when it shows a score in the 80s, is not a destination in itself — it is confirmation that a well-matched indication is following the biological arc the evidence predicts.

1. [1] The MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) 2.0 Knee Score and Atlas. (2019). https://doi.org/10.1177/1947603519865308 https://doi.org/10.1177/1947603519865308
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
5. [5] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z